Business
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026China’s NMPA has accepted the sBLA for zanidatamab; the U.S. FDA has granted Breakthrough Therapy Designation to zanidatamab in combination with fluoropyrimidine- and platinum-based chemotherapy (±) TEVIMBRA, for this ind
About this update from Zymeworks Inc.
[{"type":"image","alt":"Zymeworks Inc.","displaySize":"","headline":null,"caption":"Zymeworks Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HDrk4zPdXY7O9dYc2Rtn1g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MA--/https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f","width":300,"height":107}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026","length":279,"tagName":"p"}]},{"val":[{"type":"text","content":"China’s NMPA has accepted the sBLA for zanidatamab; the U.S. FDA has granted Breakthrough Therapy Designation to zanidatamab in combination with fluoropyrimidine- and platinum-based chemotherapy (±) TEVIMBRA, for this indication.","length":229,"tagName":"p"}]},{"val":[{"type":"text","content":"Presented new data from our Phase 1 trial of ZW191 at AACR, continuing to support best-in-class potential in ovarian and endometrial cancers","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Presented on emerging RAS inhibitor antibody-drug conjugate platform at AACR","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"$95.8 million utilized for share repurchases as of May 6, 2026 under the current authorized share repurchase program","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported $403.8 million in cash, cash equivalents and marketable securities as of March 31, 2026","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Conference call with management today at 4:30 p.m. Eastern Time (ET)","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1014,"olType":false},{"type":"text","content":"VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the first...